KDR and neoplasm: In a recent study, anlotinib mainly inhibited angiogenesis and tissue tumour cell migration by inhibiting c-Kit, VEGFR2, VEGFR3, FGFR1-4, PDGFR α and β, and other targets, thus inhibiting tumour [7, 8].